Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900691 · ClinicalTrials.gov registry record · NA
Removal of the Evolution® Esophageal Stent - Fully Covered
A NA study of Esophageal Neoplasms and Esophageal Stenosis, sponsored by Cook Group Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
- 11
- Study locations
NCT01900691: Completed NA study of Esophageal Neoplasms and Esophageal Stenosis, sponsored by Cook Group Incorporated.
NCT01900691 is a NA study of Esophageal Neoplasms and Esophageal Stenosis that has completed, run by Cook Group Incorporated. The registered enrollment target is 130 participants, below the 1,478-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (91% lower). The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900691, a NA study of Esophageal Neoplasms and Esophageal Stenosis, has completed, sponsored by Cook Group Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
- 11
- Study locations
Study Summary
The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
Primary Outcome
The study design allowed for 130 patients to be enrolled to ensure that 58 patients had an attempted endoscopic stent removal between 7 days and 6 months in order to assess the primary measure as per sample size calculation. Therefore, the first 58 patients (malignant or benign lesions) with data submitted regarding attempted endoscopic stent removal are included in this outcome measure. Successful stent removal is one in which the study stent is completely removed from the patient during a sing
Conditions Studied
Interventions
- DEVICE Evolution® Esophageal Stent - Fully Covered
Study Locations (11)
Arizona
- Mayo Clinic - Phoenix
California
- Harbor-University of California Los Angeles Medical Center - Torrance
Georgia
- Emory University Hospital - Atlanta
Illinois
- Loyola University Medical Center - Maywood
Kentucky
- University of Louisville, Division of Surgical Oncology - Louisville
Mississippi
- University of Mississippi Medical Center - Jackson
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2013-09 |
| Est. Completion | 2018-12-10 |
| Phase | NA |
What the finished NCT01900691 record still lists
NCT01900691 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,478-participant average among 12 other Esophageal Neoplasms trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Esophageal Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Evolution® Esophageal Stent - Fully Covered is the first listed.
NCT01900691 lists 11 locations in 11 states (Arizona, California, Georgia).
Frequently Asked Questions
What is clinical trial NCT01900691 about?
NCT01900691 is a clinical study titled "Removal of the Evolution® Esophageal Stent - Fully Covered". The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
What is the current status of trial NCT01900691?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2013-09. Estimated completion is 2018-12-10.
What conditions does trial NCT01900691 study?
This clinical trial studies the following conditions: Esophageal Neoplasms, Esophageal Stenosis, Esophageal Fistula, Esophageal Perforation, Stents.
What interventions are being tested in trial NCT01900691?
The interventions under investigation include: Evolution® Esophageal Stent - Fully Covered (DEVICE).
Who is sponsoring clinical trial NCT01900691?
This trial is sponsored by Cook Group Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01900691 being conducted?
This trial has 11 study locations across Arizona, California, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01900691's enrollment target sits among peer trials
130 9th of 12 higher than 4 of 12 other Esophageal Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
RECRUITING · Phase 1
-
Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)
RECRUITING
-
Mayo Clinic Upper Digestive Disease Survey
RECRUITING
-
Distribution of Lymph Node Metastases in Esophageal Carcinoma
RECRUITING
-
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia